You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
AstraZeneca
Dow
Moodys

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Patent: 9,260,721

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,260,721
Title:Expression vector and methods of producing high levels of proteins
Abstract: A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or a functional variant thereof, b) an intron, c) TPL or a functional variant thereof, d) VA gene or a functional variant thereof, and e) a bovine growth hormone polyadenylation sequence or a functional variant thereof.
Inventor(s): Singh; Arun K. (Gujarat, IN), Goel; Ashish (Gujarat, IN), Mendiratta; Sanjeev K. (Gujarat, IN)
Assignee: Cadila Healthcare Limited (Ahmedabad, IN)
Application Number:13/471,501
Patent Claims:see list of patent claims

Details for Patent 9,260,721

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Cadila Healthcare Limited (Ahmedabad, IN) 2025-06-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Johnson and Johnson
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.